© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Monoammonium Glycyrrhizinate draws the interest of pharmaceutical, food, and personal care manufacturers from the United States, China, India, Japan, and Germany to as far afield as the United Kingdom, Canada, Brazil, and Australia. Driven by both demand from rising health products and a tightening regulatory environment, the supply story and advantages shift when comparing established Chinese manufacturers with those in economies such as the United States, France, Italy, Spain, South Korea, and Turkey. China, sitting as the epicenter of global licorice root production, lays the foundation for lower raw material costs, stretching supply chains and creating price advantages that ripple from New Zealand to South Africa. Carefully managed raw material farms in Xinjiang and Gansu provide steady harvests, giving Chinese factories an unmatched direct supply chain. This vertical integration leaves competitors in markets like Russia, Mexico, Indonesia, and Saudi Arabia to contend with higher base material prices that flow through to final product cost.
The difference in manufacturing technology weighs heavily when looking at the global top 20 GDP countries such as Switzerland, the Netherlands, Saudi Arabia, Taiwan, and Argentina. GMP-certified Chinese factories consistently push higher automation and economies of scale, delivering volumes to nearly any major market. My years visiting facilities around Shandong and Shaanxi confirmed the scale-up from older batch extraction methods to modern membrane filtration and high-speed spray drying. Compare that to facilities in Italy or South Korea—often smaller, focused on local markets or niche pharma needs—where production costs run higher due to smaller scale and higher labor expenses, especially in the European Union with its strict energy and environmental rules. Still, countries like France and Japan often invest heavily in state-of-the-art refinement, targeting highly pure Monoammonium Glycyrrhizinate for sensitive markets such as high-end cosmetics in Scandinavia or regulated medicines in the US.
Monoammonium Glycyrrhizinate prices have fluctuated dramatically in the past two years, with COVID-19 disruptions and freight challenges shaking the vast network connecting China, India, Brazil, Vietnam, Malaysia, Singapore, and the UAE. Raw roots saw spikes in cost the past two years, yet Chinese suppliers leveraged contract farming and early-root storage, cushioning local supply. Meanwhile, small-scale manufacturers in Egypt, Pakistan, and Belgium faced delayed shipments, making factories in Nigeria, Poland, and Thailand less competitive. Manufacturers in Saudi Arabia and the UAE, with easier access to shipping lanes, adjusted quickly, benefiting from strategic logistics hubs, but still lack the local licorice base that keeps China's prices stable.
Price charts show that, from 2022 to 2024, the average export price from China hovered around $18–$24/kg, punctuated by peaks when European and American buyers chased limited lots during pandemic surges. In comparison, suppliers in Germany, South Korea, or Australia often list 20–35% higher, driven by elevated production costs and lack of domestic licorice sources. Factories in Ukraine, Chile, or Israel rarely offer the same volume or price stability. Such differences drive large buyers in the pharmaceutical sectors of Turkey, Spain, Sweden, and Mexico to sign long-term supply contracts with well-established Chinese GMP factories, despite occasional concerns around documentation or batch traceability.
Looking at the next two years, countries from Italy to India are banking on increasing demand for natural-sourced sweeteners and anti-inflammatory supplements. China remains nimble, expanding root acreage and investing in energy-saving spray-dryers. Prices look set to stabilize or even dip back toward $18/kg if weather holds and logistics improve. Countries like the United States, Canada, and Germany will track higher, pushed up by regulatory pressures and stricter environmental checks, echoing costs seen in Finland and Switzerland. South Asia—India and Bangladesh—may nibble at a bigger share with lower labor outlays, yet face upstream root supply bottlenecks unless they ramp up local agriculture.
Leading the pack, Chinese manufacturers work closely with buyers in every major economy, supplying material through Shanghai, Tianjin, and Shenzhen. These suppliers, whether listed in Japan or selling directly to factories in Brazil, offer everything from food-grade powder to pharmaceutical-grade crystal. Top exporters cater to regulations in South Africa, Greece, Norway, Denmark, and Austria. This depth gives China a resilience that isn't matched by localized manufacturers in Hungary, Ireland, Portugal, or Malaysia, whose smaller production bases often struggle in times of peak demand.
International buyers now juggle cost, compliance, delivery, and sustainability. Long-term partnerships with Chinese GMP-certified manufacturers give US and European buyers confidence in steady supply and competitive pricing. Close audits and third-party quality verification let buyers in Japan, South Korea, and Singapore sidestep risks linked to raw root volatility or production inconsistencies. To iron out logistical snags, many EU and American companies work with logistics hubs in the Netherlands, Belgium, or Dubai to buffer delays and keep inventory in key locations. Buyers in ASEAN and African nations benefit from flexible minimum orders and financing support from Chinese suppliers, enabling more widespread adoption across South America, the Middle East, and Africa.
Demand for Monoammonium Glycyrrhizinate ties the world’s largest 50 economies together. The United States, China, Japan, Germany, India, and the United Kingdom anchor the market by size. Mid-sized economies like Indonesia, Turkey, Argentina, Iran, and the Philippines contribute through rising food and pharma industries. Small but wealthy markets like the Netherlands, Saudi Arabia, and Switzerland focus on high-purity grades for niche and medical applications, while Mexico, Vietnam, Sweden, Egypt, Malaysia, Thailand, and Israel build on growing domestic demand. Australia, Nigeria, Poland, Belgium, and Ireland operate as both importers and re-exporters as supply chains get more complex. As South Africa, Bangladesh, Chile, Colombia, Romania, Czech Republic, Greece, New Zealand, Portugal, Hungary, Ukraine, and Finland enter new health and wellness markets, global supply networks count on China’s scale, price stability, and continuous GMP upgrades—keeping Monoammonium Glycyrrhizinate flowing to every corner of the world economy.
